STOCK TITAN

[8-K] Logan Ridge Finance Corporation Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Evolent Health, Inc. (EVH) filed a Form 4 reporting an equity-based compensation grant to President Daniel J. McCarthy. On 07/01/2025 Mr. McCarthy received 44,767 Class A common shares in the form of restricted stock units (RSUs) under the Amended and Restated 2015 Omnibus Incentive Compensation Plan at an effective purchase price of $0.00. Following the award, his aggregate beneficial ownership increased to 433,771 shares.

The award vests on a staggered schedule: 34 % on 07/01/2026, and 33 % on each of 07/01/2027 and 07/01/2028. These RSUs represent the second portion of the annual grant cycle; issuance was contingent on shareholder approval of additional plan shares, which occurred at the 06/05/2025 annual meeting.

No derivative securities were reported, and the filing indicates direct ownership. The transaction neither involved open-market purchases nor sales; therefore, it does not immediately alter the public float but does expand future fully-diluted share count once the RSUs settle.

Evolent Health, Inc. (EVH) ha presentato un Modulo 4 segnalando una concessione di compensi basati su azioni al Presidente Daniel J. McCarthy. Il 01/07/2025 il Sig. McCarthy ha ricevuto 44.767 azioni ordinarie di Classe A sotto forma di unità azionarie vincolate (RSU) nell'ambito del Piano di Incentivi Omnibus Modificato e Rifinanziato del 2015, con un prezzo di acquisto effettivo di 0,00 $. Dopo la concessione, la sua proprietà beneficiaria complessiva è aumentata a 433.771 azioni.

La maturazione del premio avviene secondo un calendario scaglionato: 34% il 01/07/2026 e 33% rispettivamente il 01/07/2027 e il 01/07/2028. Queste RSU rappresentano la seconda parte del ciclo annuale di assegnazione; l'emissione era subordinata all'approvazione da parte degli azionisti di ulteriori azioni del piano, avvenuta nell'assemblea annuale del 05/06/2025.

Non sono stati segnalati strumenti derivati e la dichiarazione indica proprietà diretta. La transazione non ha coinvolto acquisti o vendite sul mercato aperto; pertanto, non modifica immediatamente il flottante pubblico ma aumenta il numero totale di azioni diluite in futuro una volta che le RSU saranno liquidate.

Evolent Health, Inc. (EVH) presentó un Formulario 4 informando sobre una concesión de compensación basada en acciones al presidente Daniel J. McCarthy. El 01/07/2025 el Sr. McCarthy recibió 44,767 acciones ordinarias Clase A en forma de unidades de acciones restringidas (RSU) bajo el Plan de Compensación Incentivada Omnibus Modificado y Reformulado de 2015, con un precio efectivo de compra de $0.00. Tras la concesión, su propiedad beneficiaria total aumentó a 433,771 acciones.

La adjudicación se consolida según un calendario escalonado: 34% el 01/07/2026, y 33% el 01/07/2027 y el 01/07/2028. Estas RSU representan la segunda parte del ciclo anual de concesiones; la emisión estaba condicionada a la aprobación de los accionistas para acciones adicionales del plan, que se realizó en la reunión anual del 05/06/2025.

No se reportaron valores derivados y la presentación indica propiedad directa. La transacción no implicó compras ni ventas en el mercado abierto; por lo tanto, no altera inmediatamente el flotante público, pero sí incrementa el recuento total de acciones totalmente diluidas una vez que las RSU se liquiden.

Evolent Health, Inc. (EVH)는 Daniel J. McCarthy 사장에게 주식 기반 보상 부여를 보고하는 Form 4를 제출했습니다. 2025년 7월 1일, McCarthy 씨는 개정 및 재작성된 2015년 총괄 인센티브 보상 계획에 따라 44,767주의 Class A 보통주를 제한 주식 단위(RSU) 형태로 무상으로 받았습니다. 이 보상 후 그의 총 실질 소유 주식 수는 433,771주로 증가했습니다.

보상은 단계별로 권리 확정되며: 2026년 7월 1일에 34%, 그리고 2027년 7월 1일과 2028년 7월 1일에 각각 33%입니다. 이 RSU는 연간 부여 주기의 두 번째 부분을 나타내며, 발행은 2025년 6월 5일 주주총회에서 추가 계획 주식 승인을 조건으로 했습니다.

파생 증권은 보고되지 않았으며, 제출서에는 직접 소유권이 명시되어 있습니다. 이 거래는 공개 시장에서의 매매가 아니므로 즉시 유통 주식 수에는 영향을 미치지 않지만, RSU가 정산되면 미래의 완전 희석 주식 수는 증가합니다.

Evolent Health, Inc. (EVH) a déposé un formulaire 4 signalant une attribution de rémunération en actions au président Daniel J. McCarthy. Le 01/07/2025, M. McCarthy a reçu 44 767 actions ordinaires de Classe A sous forme d’unités d’actions restreintes (RSU) dans le cadre du plan de rémunération incitative omnibus modifié et révisé de 2015, avec un prix d’achat effectif de 0,00 $. Après cette attribution, sa propriété bénéficiaire totale a augmenté à 433 771 actions.

L’attribution est soumise à un calendrier d’acquisition échelonné : 34 % le 01/07/2026, puis 33 % les 01/07/2027 et 01/07/2028. Ces RSU représentent la deuxième partie du cycle annuel d’attribution ; leur émission dépendait de l’approbation des actionnaires pour des actions supplémentaires du plan, laquelle a eu lieu lors de l’assemblée générale annuelle du 05/06/2025.

Aucun titre dérivé n’a été déclaré et le dépôt indique une propriété directe. La transaction n’a impliqué ni achats ni ventes sur le marché ouvert ; elle ne modifie donc pas immédiatement le flottant public, mais augmente le nombre total d’actions entièrement diluées une fois que les RSU seront réglées.

Evolent Health, Inc. (EVH) hat ein Formular 4 eingereicht, in dem eine aktienbasierte Vergütung an Präsident Daniel J. McCarthy gemeldet wird. Am 01.07.2025 erhielt Herr McCarthy 44.767 Class A Stammaktien in Form von Restricted Stock Units (RSUs) im Rahmen des geänderten und neu gefassten Omnibus-Incentive-Compensation-Plans von 2015 zu einem effektiven Kaufpreis von 0,00 $. Nach der Zuteilung stieg sein gesamtes wirtschaftliches Eigentum auf 433.771 Aktien.

Die Zuteilung vestet gestaffelt: 34 % am 01.07.2026 und jeweils 33 % am 01.07.2027 und 01.07.2028. Diese RSUs stellen den zweiten Teil des jährlichen Zuteilungszyklus dar; die Ausgabe war abhängig von der Zustimmung der Aktionäre zu zusätzlichen Planaktien, die auf der Hauptversammlung am 05.06.2025 erfolgte.

Es wurden keine Derivate gemeldet, und die Einreichung weist auf direktes Eigentum hin. Die Transaktion beinhaltete weder Käufe noch Verkäufe am offenen Markt; daher ändert sie den Streubesitz nicht unmittelbar, erhöht jedoch die zukünftige vollständig verwässerte Aktienanzahl, sobald die RSUs ausgegeben werden.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Standard multi-year RSU grant aligns the president’s incentives with shareholders; limited immediate impact.

The filing reflects routine equity compensation rather than discretionary insider buying. A three-year vesting schedule encourages management retention and long-term value creation, consistent with governance best practices. Because shares were issued under an already-approved plan, the governance risk is low. Investors should note that settlement will incrementally increase diluted share count, but the magnitude—~0.05 % of 83 million shares outstanding (based solely on grant size)—is immaterial to ownership structure. Overall, I view the disclosure as neutral with a slight positive tilt toward alignment.

TL;DR: Grant adds 44.8k RSUs; expense will amortize over three years, modestly affecting EPS dilution.

The RSUs will generate non-cash stock-based compensation expense over the 2026-2028 period, marginally lowering reported GAAP earnings. Assuming a mid-$30 share price, the fair-value cost approximates $1.5 million, insignificant versus EVH’s trailing twelve-month revenue base. No cash outflow occurs, preserving liquidity. Given the small scale and predictable amortization, I classify the impact as neutral for valuation models.

Evolent Health, Inc. (EVH) ha presentato un Modulo 4 segnalando una concessione di compensi basati su azioni al Presidente Daniel J. McCarthy. Il 01/07/2025 il Sig. McCarthy ha ricevuto 44.767 azioni ordinarie di Classe A sotto forma di unità azionarie vincolate (RSU) nell'ambito del Piano di Incentivi Omnibus Modificato e Rifinanziato del 2015, con un prezzo di acquisto effettivo di 0,00 $. Dopo la concessione, la sua proprietà beneficiaria complessiva è aumentata a 433.771 azioni.

La maturazione del premio avviene secondo un calendario scaglionato: 34% il 01/07/2026 e 33% rispettivamente il 01/07/2027 e il 01/07/2028. Queste RSU rappresentano la seconda parte del ciclo annuale di assegnazione; l'emissione era subordinata all'approvazione da parte degli azionisti di ulteriori azioni del piano, avvenuta nell'assemblea annuale del 05/06/2025.

Non sono stati segnalati strumenti derivati e la dichiarazione indica proprietà diretta. La transazione non ha coinvolto acquisti o vendite sul mercato aperto; pertanto, non modifica immediatamente il flottante pubblico ma aumenta il numero totale di azioni diluite in futuro una volta che le RSU saranno liquidate.

Evolent Health, Inc. (EVH) presentó un Formulario 4 informando sobre una concesión de compensación basada en acciones al presidente Daniel J. McCarthy. El 01/07/2025 el Sr. McCarthy recibió 44,767 acciones ordinarias Clase A en forma de unidades de acciones restringidas (RSU) bajo el Plan de Compensación Incentivada Omnibus Modificado y Reformulado de 2015, con un precio efectivo de compra de $0.00. Tras la concesión, su propiedad beneficiaria total aumentó a 433,771 acciones.

La adjudicación se consolida según un calendario escalonado: 34% el 01/07/2026, y 33% el 01/07/2027 y el 01/07/2028. Estas RSU representan la segunda parte del ciclo anual de concesiones; la emisión estaba condicionada a la aprobación de los accionistas para acciones adicionales del plan, que se realizó en la reunión anual del 05/06/2025.

No se reportaron valores derivados y la presentación indica propiedad directa. La transacción no implicó compras ni ventas en el mercado abierto; por lo tanto, no altera inmediatamente el flotante público, pero sí incrementa el recuento total de acciones totalmente diluidas una vez que las RSU se liquiden.

Evolent Health, Inc. (EVH)는 Daniel J. McCarthy 사장에게 주식 기반 보상 부여를 보고하는 Form 4를 제출했습니다. 2025년 7월 1일, McCarthy 씨는 개정 및 재작성된 2015년 총괄 인센티브 보상 계획에 따라 44,767주의 Class A 보통주를 제한 주식 단위(RSU) 형태로 무상으로 받았습니다. 이 보상 후 그의 총 실질 소유 주식 수는 433,771주로 증가했습니다.

보상은 단계별로 권리 확정되며: 2026년 7월 1일에 34%, 그리고 2027년 7월 1일과 2028년 7월 1일에 각각 33%입니다. 이 RSU는 연간 부여 주기의 두 번째 부분을 나타내며, 발행은 2025년 6월 5일 주주총회에서 추가 계획 주식 승인을 조건으로 했습니다.

파생 증권은 보고되지 않았으며, 제출서에는 직접 소유권이 명시되어 있습니다. 이 거래는 공개 시장에서의 매매가 아니므로 즉시 유통 주식 수에는 영향을 미치지 않지만, RSU가 정산되면 미래의 완전 희석 주식 수는 증가합니다.

Evolent Health, Inc. (EVH) a déposé un formulaire 4 signalant une attribution de rémunération en actions au président Daniel J. McCarthy. Le 01/07/2025, M. McCarthy a reçu 44 767 actions ordinaires de Classe A sous forme d’unités d’actions restreintes (RSU) dans le cadre du plan de rémunération incitative omnibus modifié et révisé de 2015, avec un prix d’achat effectif de 0,00 $. Après cette attribution, sa propriété bénéficiaire totale a augmenté à 433 771 actions.

L’attribution est soumise à un calendrier d’acquisition échelonné : 34 % le 01/07/2026, puis 33 % les 01/07/2027 et 01/07/2028. Ces RSU représentent la deuxième partie du cycle annuel d’attribution ; leur émission dépendait de l’approbation des actionnaires pour des actions supplémentaires du plan, laquelle a eu lieu lors de l’assemblée générale annuelle du 05/06/2025.

Aucun titre dérivé n’a été déclaré et le dépôt indique une propriété directe. La transaction n’a impliqué ni achats ni ventes sur le marché ouvert ; elle ne modifie donc pas immédiatement le flottant public, mais augmente le nombre total d’actions entièrement diluées une fois que les RSU seront réglées.

Evolent Health, Inc. (EVH) hat ein Formular 4 eingereicht, in dem eine aktienbasierte Vergütung an Präsident Daniel J. McCarthy gemeldet wird. Am 01.07.2025 erhielt Herr McCarthy 44.767 Class A Stammaktien in Form von Restricted Stock Units (RSUs) im Rahmen des geänderten und neu gefassten Omnibus-Incentive-Compensation-Plans von 2015 zu einem effektiven Kaufpreis von 0,00 $. Nach der Zuteilung stieg sein gesamtes wirtschaftliches Eigentum auf 433.771 Aktien.

Die Zuteilung vestet gestaffelt: 34 % am 01.07.2026 und jeweils 33 % am 01.07.2027 und 01.07.2028. Diese RSUs stellen den zweiten Teil des jährlichen Zuteilungszyklus dar; die Ausgabe war abhängig von der Zustimmung der Aktionäre zu zusätzlichen Planaktien, die auf der Hauptversammlung am 05.06.2025 erfolgte.

Es wurden keine Derivate gemeldet, und die Einreichung weist auf direktes Eigentum hin. Die Transaktion beinhaltete weder Käufe noch Verkäufe am offenen Markt; daher ändert sie den Streubesitz nicht unmittelbar, erhöht jedoch die zukünftige vollständig verwässerte Aktienanzahl, sobald die RSUs ausgegeben werden.

0001571329False00015713292025-06-202025-06-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 20, 2025
Logan Ridge Finance Corporation
(Exact name of Registrant as specified in its charter)
Maryland814-0102290-0945675
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
650 Madison Avenue, 3rd Floor
New York
,
New York
10022
(Address of principal executive offices)(Zip Code)
(Registrant’s telephone number, including area code): (212) 891-2880
None
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange
on which registered
Common Stock, par value $0.01 per shareLRFCThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 20, 2025, Logan Ridge Finance Corporation (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders approved one proposal as set forth below. The proposal is described in detail in the definitive proxy statement for the Special Meeting as filed by Portman Ridge Finance Corporation (“PTMN”) with the Securities and Exchange Commission on May 13, 2025.
Proposal: The Company’s stockholders approved the merger of Portman Ridge Merger Sub Inc., a Maryland corporation and a direct wholly-owned subsidiary of PTMN (“Merger Sub”) with and into the Company (the “Merger”), with the Company continuing as the surviving company and as a wholly-owned subsidiary of PTMN pursuant to the Agreement and Plan of Merger, dated as of January 29, 2025 (the “Merger Agreement”), by and among the Company; Merger Sub; PTMN; solely for the limited purposes therein, Mount Logan Management, LLC, a Delaware limited liability company and the external investment adviser to the Company; and, solely for the limited purposes therein, Sierra Crest Investment Management, LLC, a Delaware limited liability company and the external investment adviser to PTMN. Immediately after the effectiveness of the Merger, the Company will merge with and into PTMN, with PTMN continuing as the surviving company. The Company’s stockholders approved the Merger based on the following votes:
FORAGAINSTABSTAINBROKER NON-VOTE
1,628,011192,3904,6950
Item 7.01. Regulation FD Disclosure.
On June 20, 2025, the Company issued a press release announcing that the stockholders of the Company have approved the proposal related to the previously announced merger of the Company into PTMN at the Special Meeting. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed” for any purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section. The information in this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
Exhibit
99.1
Press Release, dated June 20, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LOGAN RIDGE FINANCE CORPORATION
By:/s/ Brandon Satoren
Name:Brandon Satoren
Title:Chief Financial Officer
Date: June 20, 2025

FAQ

How many EVH shares did President Daniel McCarthy receive on 07/01/2025?

He was granted 44,767 restricted stock units representing Class A common shares.

What is the vesting schedule for the new EVH RSUs?

The award vests 34 % on 07/01/2026 and 33 % on both 07/01/2027 and 07/01/2028.

Did Daniel McCarthy purchase EVH shares with cash?

No. The Form 4 reports a stock grant at $0 purchase price; there was no open-market purchase.

How many EVH shares does the president now beneficially own?

After the grant, Mr. McCarthy beneficially owns 433,771 shares of Class A common stock.

Was shareholder approval required for this EVH equity award?

Yes. Shareholders approved additional shares under the 2015 Omnibus Incentive Plan on 06/05/2025, enabling the grant.
Logan Ridge Finance Corp

NASDAQ:LRFC

LRFC Rankings

LRFC Latest News

LRFC Stock Data

50.17M
2.38M
10.24%
29.33%
0.22%
Asset Management
Financial Services
Link
United States
NEW YORK